Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04005690 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

StatusRecruiting
PhaseEarly Phase 1
Started2019-08-01
View on ClinicalTrials.gov ↗
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.

Amendment history 1 change detected by DataLookout

2026-09-05
Primary completion pushed: 2026-06-01 → 2027-06-01
Trial Details
NCT Number NCT04005690
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: American Association for Cancer Research, Oregon Health and Science University, Genentech, Inc., Cardiff Oncology
Conditions Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Enrollment 90 participants
Start Date 2019-08-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-04